Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
EDQM
0
USP
0
JP
0
Others
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
US Medicaid
NA
Annual Reports
NA
Regulatory FDF Prices
NA
0
FDF
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers


1. R 848
2. R-848
3. R848 Compound
1. 144875-48-9
2. R-848
3. 1-(4-amino-2-(ethoxymethyl)-1h-imidazo[4,5-c]quinolin-1-yl)-2-methylpropan-2-ol
4. 1-[4-amino-2-(ethoxymethyl)-1h-imidazo[4,5-c]quinolin-1-yl]-2-methylpropan-2-ol
5. Resiquimod [inn]
6. R 848
7. Resiquimod (r-848)
8. R848
9. S 28463
10. S-28463
11. V3dmu7pvxf
12. Mfcd00937759
13. Chembl383322
14. Chebi:36706
15. 1-[4-amino-2-(ethoxymethyl)imidazo[4,5-c]quinolin-1-yl]-2-methylpropan-2-ol
16. Cd11301
17. Cd-11301
18. R848;s28463
19. 2252319-44-9
20. 1-(4-amino-2-(ethoxymethyl)-1h-imidazo[4,5-c]quinolin-1-yl)-2-methylpropan-2-ol.
21. 1h-imidazo[4,5-c]quinoline-1-ethanol, 4-amino-2-(ethoxymethyl)-alpha,alpha-dimethyl-
22. 4-amino-2-(ethoxymethyl)-alpha,alpha-dimethyl-1h-imidazo[4,5-c]quinoline-1-ethanol
23. R848 Compound
24. Unii-v3dmu7pvxf
25. 1h-imidazo(4,5-c)quinoline-1-ethanol, 4-amino-2-(ethoxymethyl)-alpha,alpha-dimethyl-
26. 4-amino-2-(ethoxymethyl)-alpha,alpha-dimethyl-1h-imidazo(4,5-c)quinoline-1-ethanol
27. Resiquimodr848
28. Vml-600
29. Rx8
30. R848; Resiquimod
31. S28463
32. Resiquimod [mi]
33. Resiquimod [usan]
34. Resiquimod [mart.]
35. Resiquimod [who-dd]
36. Schembl34159
37. Mls006010212
38. Alpha-dimethyl-1h-imidazo(4,5-c)quinoline-1-ethanol
39. Gtpl5051
40. Dtxsid7040603
41. Resiquimod, >=98% (hplc)
42. Hms3740o09
43. Bcp09103
44. Ex-a1879
45. Bdbm50241029
46. S8133
47. Zinc28572103
48. Akos016003509
49. Ccg-267635
50. Cs-1706
51. Db06530
52. Sb17111
53. 1-(4-amino-2-ethoxymethyl-imidazo[4,5-c]quinolin-1-yl)-2-methyl-propan-2-ol
54. Ncgc00370784-01
55. Ncgc00370784-05
56. Ac-35716
57. As-30885
58. Hy-13740
59. Smr002530531
60. Sy107476
61. Ft-0763049
62. R0197
63. Resiquimod, Vml-600, R-848, S-28463
64. A856222
65. Q426054
66. Sr-01000944954
67. J-008020
68. Sr-01000944954-1
69. 1-[4-amino-2-(ethoxymethyl)imidazo[4,5-c]quinolin-1-yl]-2-methyl-propan-2-ol
70. 4-amino-2-ethoxymethyl-alpha,alpha-dimethyl-1h-imidazo[4,5-c]quinoline-1-ethanol
71. 4-amino-alpha,alpha-dimethyl-2-ethoxymethyl-1h-imidazo[4,5-c]quinolin-1-ethanol
72. 4-amino-alpha,alpha-dimethyl-2-ethoxymethyl-1h-imidazo[4,5-c]quinoline-1-ethanol
| Molecular Weight | 314.4 g/mol |
|---|---|
| Molecular Formula | C17H22N4O2 |
| XLogP3 | 1.3 |
| Hydrogen Bond Donor Count | 2 |
| Hydrogen Bond Acceptor Count | 5 |
| Rotatable Bond Count | 5 |
| Exact Mass | 314.17427596 g/mol |
| Monoisotopic Mass | 314.17427596 g/mol |
| Topological Polar Surface Area | 86.2 Ų |
| Heavy Atom Count | 23 |
| Formal Charge | 0 |
| Complexity | 406 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Investigated for use/treatment in genital herpes.
Resiquimod is a Toll-like receptor 7 (TLR7) and TLR8 agonist that is a potent inducer of alpha interferon (IFN-alpha) and other cytokines.
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
The funding will be used for the further development of company's intraoperative immunotherapy, SURGERx with resiquimod (STM-416), in patients with recurrent bladder cancer.
Lead Product(s): Resiquimod,Inapplicable
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase I/ Phase IIProduct Type: Miscellaneous
Sponsor: Bioluminescence Ventures
Deal Size: $32.0 million Upfront Cash: Undisclosed
Deal Type: Series B Financing July 19, 2023

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Resiquimod,Inapplicable
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Partner/Sponsor/Collaborator : Bioluminescence Ventures
Deal Size : $32.0 million
Deal Type : Series B Financing
Details : The funding will be used for the further development of company's intraoperative immunotherapy, SURGERx with resiquimod (STM-416), in patients with recurrent bladder cancer.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
July 19, 2023

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
STM-416 (Resiquimod), is a TLR7 and TLR8 agonist which is being invstigated for prevention of recurrence or progression after transurethral resection of bladder tumor (TURBT) in patients with non-muscle invasive bladder cancer (NMIBC)
Lead Product(s): Resiquimod,Inapplicable
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: IND EnablingProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable January 04, 2023

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Resiquimod,Inapplicable
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : STM-416 (Resiquimod), is a TLR7 and TLR8 agonist which is being invstigated for prevention of recurrence or progression after transurethral resection of bladder tumor (TURBT) in patients with non-muscle invasive bladder cancer (NMIBC)
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
January 04, 2023

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
TransCon TLR7/8 Agonist is an investigational long-acting prodrug of resiquimod, a small molecule agonist of Toll-like receptors (TLR) 7 and 8 designed to provide sustained activation of intratumoral antigen-presenting cells driving tumor antigen presentation.
Lead Product(s): Resiquimod,Inapplicable
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase I/ Phase IIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable November 11, 2022

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Resiquimod,Inapplicable
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Dose Escalation Data From TranscendIT-101, Ascendis Pharma’s Phase 1/2 Trial of TransCon™ TLR7...
Details : TransCon TLR7/8 Agonist is an investigational long-acting prodrug of resiquimod, a small molecule agonist of Toll-like receptors (TLR) 7 and 8 designed to provide sustained activation of intratumoral antigen-presenting cells driving tumor antigen present...
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
November 11, 2022

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Resiquimod, a small molecule agonist of Toll-like receptors, is designed to provide sustained activation of intratumoral antigen presenting cells driving tumor antigen presentation and induction of immune stimulatory cytokines in the tumor.
Lead Product(s): Resiquimod,Inapplicable
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase I/ Phase IIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable December 07, 2021

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Resiquimod,Inapplicable
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Ascendis Pharma A/S to Host Virtual R&D Program Update on December 14
Details : Resiquimod, a small molecule agonist of Toll-like receptors, is designed to provide sustained activation of intratumoral antigen presenting cells driving tumor antigen presentation and induction of immune stimulatory cytokines in the tumor.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
December 07, 2021

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
CD11301 is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Lymphoma, T-Cell, Cutaneous.
Lead Product(s): Resiquimod,Inapplicable
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable September 25, 2017

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Resiquimod,Inapplicable
Therapeutic Area : Oncology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : CD11301 is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Lymphoma, T-Cell, Cutaneous.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
September 25, 2017

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Resiquimod is a Other Small Molecule drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Carcinoma, Basal Cell.
Lead Product(s): Resiquimod,Inapplicable
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase I/ Phase IIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable March 11, 2013

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Resiquimod,Inapplicable
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Resiquimod is a Other Small Molecule drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Carcinoma, Basal Cell.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
March 11, 2013

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Resiquimod is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Keratosis, Actinic.
Lead Product(s): Resiquimod,Inapplicable
Therapeutic Area: Dermatology Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable April 24, 2012

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Resiquimod,Inapplicable
Therapeutic Area : Dermatology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Resiquimod is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Keratosis, Actinic.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
April 24, 2012

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Market Place
ABOUT THIS PAGE
87
PharmaCompass offers a list of Resiquimod API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, and more, enabling you to easily find the right Resiquimod manufacturer or Resiquimod supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Resiquimod manufacturer or Resiquimod supplier.
A Resiquimod manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Resiquimod, including repackagers and relabelers. The FDA regulates Resiquimod manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Resiquimod API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Resiquimod supplier is an individual or a company that provides Resiquimod active pharmaceutical ingredient (API) or Resiquimod finished formulations upon request. The Resiquimod suppliers may include Resiquimod API manufacturers, exporters, distributors and traders.
click here to find a list of Resiquimod suppliers with USDMF, JDMF, KDMF, CEP, GMP, and COA related information on PharmaCompass.
A Resiquimod DMF (Drug Master File) is a document detailing the whole manufacturing process of Resiquimod active pharmaceutical ingredient (API) in detail. Different forms of Resiquimod DMFs exist exist since differing nations have different regulations, such as Resiquimod USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Resiquimod DMF submitted to regulatory agencies in the US is known as a USDMF. Resiquimod USDMF includes data on Resiquimod's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Resiquimod USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Resiquimod suppliers with USDMF on PharmaCompass.
Resiquimod Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Resiquimod GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, and more, enabling you to easily find the right Resiquimod GMP manufacturer or Resiquimod GMP API supplier for your needs.
A Resiquimod CoA (Certificate of Analysis) is a formal document that attests to Resiquimod's compliance with Resiquimod specifications and serves as a tool for batch-level quality control.
Resiquimod CoA mostly includes findings from lab analyses of a specific batch. For each Resiquimod CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Resiquimod may be tested according to a variety of international standards, such as European Pharmacopoeia (Resiquimod EP), Resiquimod JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Resiquimod USP).